Insulin-like growth factor-II (IGF-II) is thought to play a critical role in the development of embryonic tumors such as Wilms' tumor. However, despite highly elevated IGF-II mRNA levels in tumors, IGF-II is not elevated in the serum of patients with Wilms' tumors. Recently high molecular weight forms of IGF-II ('big'-or pro-IGF-II) have been found to be produced by some tumors. In order to prove whether or not high molecular weight forms of IGF-II are produced by Wilms' tumor cells and secreted into the culture medium, we established Wilms' tumor cell lines. After column chromatography of the culture medium, IGF-II and pro-IGF-II concentrations were measured. For pro-IGF-II measurement we established a pro-IGF-II RIA using a rabbit polyclonal antiserum directed against amino acids 7-21 (E 7-21 ) of the E-domain of pro-IGF-II. Gel electrophoresis and Western blotting with anti-IGF-II antibodies revealed a band at 7.5 kDa corresponding to fully processed IGF-II and bands between 10 and 20 kDa. Using pro-IGF-II antiserum, bands between 10 and 25 kDa were detected. We conclude that in vitro cultured Wilms' tumor cells produce and release various forms of 'big IGF-II' with molecular masses between 10 and 25 kDa. It remains uncertain whether these high molecular weight forms of IGF-II represent normal precursors of IGF-II or incorrectly processed IGF-II.
Introduction
Insulin-like growth factor-II (IGF-II) is a single chain polypeptide of the insulin family (1, 2) . Besides effects on growth and metabolism of various cell types, it exerts pleiotropic effects on cells at an embryonic stage (3, 4) . Very high IGF-II gene expression patterns have been found in some tumors including central nervous system tumors (5, 6) and in a large variety of tissues during fetal development (7) (8) (9) . Although IGF-I is known to be the most important postnatal growth factor (10, 11) , circulating IGF-II levels in adult humans are higher than the equivalent IGF-I levels presumably originating from the P1 promoter in the liver (12) . High IGF-II mRNA expression, especially in sarcomas and some common tumors in children such as Wilms' tumors (13) , is evidence for an auto/paracrine function of IGF-II during malignant transformation and tumor development (14) (15) (16) (17) (18) . We recently showed that IGF-II is synthesized and released by Wilms' tumor tissue in vitro to a higher extent than in kidneys (19, 20) . In normal tissue, IGF-II results from cleavage of a prepropeptide consisting of 156 amino acids. Before secretion the E-domain is removed step by step at the carboxyl terminal whereas the B-, C-, A-and D-domain belong to the fully processed mature 7.5 kDa IGF-II (21) (22) (23) . The number, molecular weights and biological activities of IGF-II proforms are still unknown (24) . In addition, human hepatoma cells have been shown to produce proforms of IGF-II as a result of abnormal processing (25) and antisense transcripts of the IGF-II gene have been found in Wilms' tumor (26) . To sum up, 'big-IGF-II' of different molecular weights has been found in normal tissue, serum (27) or spinal fluid (28) and has also been isolated from tumor cell cultures in vitro, such as a colon carcinoma cell line (29) , a teratocarcinoma cell line (30) or a rhabdomyosarcoma cell line (31) , with molecular masses ranging from 10 to 16 kDa. Therefore we set out to measure pro-IGF-II, produced by Wilms' tumor cells and secreted into the medium, by a newly developed radioimmunoassay using an antibody directed against amino acids 7-21 of the E-domain of pro-IGF-II (E [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] ) and to determine the molecular weights of various pro-IGF-II forms by gel electrophoresis and immunoblotting with this antibody. prestained molecular weight standards and the goat antirabbit IgG-AP Immun-Lite Chemiluminescent Assay Kit were from Bio-Rad (Hercules, CA, USA). Iodo-beads were purchased from Pierce (Rockford, IL, USA), and [ 125 I]NaI was from Amersham International (Amersham, Bucks, UK). Rabbit gamma globulin was from Calbiochem (La Jolla, CA, USA), and polyethylene glycol 6000 from Fluka AG (Buchs, Switzerland). A peptide containing amino acids 7-21 of the human pro-IGF-II E-domain E 7-21 was synthesized by Neosystem Laboratoire (Strasbourg, France).
125
I-IGF-II was from Anawa (Zurich, Switzerland). Recombinant human IGF-I was from BoehringerMannheim (Mannheim, Germany).
Methods

Cell cultures
Cell cultures were established using human Wilms' tumor tissue or kidney tissue as previously described (19, 20) . Wilms' tumor cell line (WTCL)-1 and WTCL-2 were cultured from tumor tissues which had first been transplanted into nude mice; WTCL-3 and WTCL-4 were cultured directly after surgery. A histopathological examination of the Wilms' tumor cell cultures by using markers vimentin or Lu5 (cytoceratine) and microscopically using periodic acid-Schiff or hematoxylin and eosin staining revealed homogeneous tumor cell populations, but of various degrees of differentiation. There was no evidence for contamination with nontumor cells (20) . The kidney cell cultures were examined in the same way and showed mixed cultures of different typical kidney cells.
Collection of conditioned medium
For determination of IGF-II and pro-IGF-II secretion by the Wilms' tumor cells, approximately 2 × 10 6 (WTCL-1, WTCL-2) and 0.8 × 10 6 (WTCL-3) or 1 × 10 6 (WTCL-4) tumor cells, respectively, were rinsed with PBS at pH 7.2 without Ca 2þ and Mg 2þ , plated in 100 mm plastic dishes in serum-free culture medium and maintained at 37 ЊC in 5% CO 2 . Forty-eight hours later, conditioned medium samples from tumor cell culture were collected and stored at ¹20 ЊC until chromatography on Bio-Gel P-100. The same type of cells have been used in the cell culture experiments published before by our group (20) . There cell growth of the different cultures during the 48 h period in serum-free medium was shown to be comparable. The absolute concentrations of IGF-II and pro-IGF-II are related to each other as if conditioning of the cells had always been started with 2 × 10 6 cells.
Gel permeation chromatography
After lyophilization the serum-free medium was redissolved in 2 mol/l acetic acid/0.1% Triton X-100 dependent on the needed concentration. Chromatography was performed over Bio-Gel P-100 columns (150 × 1.5 cm) in 0.5 M acetic acid (28) and 2 ml fractions collected. For calibration of column 1, cytochrome C (12.8 kDa),
125
I-IGF-I (7.5 kDa) and Trasylol (6.0 kDa) were used. With column 2 we additionally used 125 I-E 7-21 (about 2 kDa) and phenol red (367 Da) as calibration standards. After elution, fractions were again lyophilized and dissolved in 0.1 mol/l PBS (pH 7.4)/0.1% BSA for the IGF-II assay and in 0.1 mol/l NaH 2 PO 4 , 25 mmol/l EDTA, 0.02% sodium azide, 0.5% BSA and 0.05% Tween-20, pH 6.5, (21) for the pro-IGF-II E-domain assay.
Pro-IGF-II E-domain antiserum
Polyclonal antibody against the chemically synthesized sequence of amino acid 7-21 of the pro-IGF-II E-domain (E 7-21 ), coupled to thyroglobulin by Neosystem Laboratoire (Strasbourg, France), was generated in New Zealand rabbits. They were injected intradermally at multiple sites with an initial dose of 2.96 mg peptide emulsified in complete Freund's adjuvant, and 2, 7 and 13 months after the first injection subcutaneous booster injections with 1.18 mg in each were carried out. Test bleedings were performed 10 days after each booster injection. Antibody generated after the first boosting did not show satisfactory results when used in assay conditions. After the second boosting, antibody concentration and specificity rose. Figure 1 shows an example of a pro-IGF-II E-domain assay standard curve and data on parallelism with unknowns carried out with antibody generated after the second boosting. Pro-IGF-II E-domain antibody reacted well with the chemically synthesized E-domain sequence but not with the mature IGF-II either in solution or in Western blotting conditions. In Sep Pak
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Wilms' tumor high molecular weight IGF-II 397 Figure 1 Data on parallelism of standards and unknowns measured by pro-IGF-II E-domain assay using two different sera Ϯ 2.3 nmol/l E 7-21 after Sep Pak extraction, diluted 1:1, 1:2 and 1:4. W natural serum 1; X serum 1 with addition of E 7-21 ; A natural serum 2; B serum 2 with addition of E [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] . % B ¼ percent bound.
extracted serum there was no cross reaction either with addition of insulin up to 65.6 nmol/l or IGF-II up to 250 nmol/l. The third boosting did not improve antibody characteristics. For assays and Western blots we always used the antibody generated 10 days after the second boosting.
Radiolabeling of the pro-IGF-II E-domain sequence E 7-21 E 7-21 was labeled with 125 I using the Iodo-bead method according to the protocol provided by Pierce. Peptide (8 mg) dissolved in 0.1 mol/l PBS, 1 mol/l NaCl, pH 7.4, was labeled with 1 mCi of 125 I to a specific activity of 50-60 mCi/mg. Reaction time was 6 min at 8-12 ЊC. Thereafter the labeled peptide was purified over a Bio-Gel P-2 column (volume 9 ml) in 0.1 mol/l ammonium acetate/0.1% BSA. Before use in the RIA, the tracer was diluted to a concentration of 5.1 ng/ml E 7-21 with assay buffer.
Pro-IGF-II E-domain RIA procedure One hundred microliters of unlabeled E 7-21 (0.03-66 nmol/l; standard curve) or 100 ml redissolved concentrated medium were preincubated at 4 ЊC for 30 h with pro-IGF-II E-domain polyclonal antiserum 1:400 at a final dilution of 1:800. Recombinant human IGF-I (25 ng) was added to each tube before incubation to block the interaction with potential residual binding proteins after acetic acid gel filtration (32) . Thereafter 100 ml of diluted tracer ( 125 I-E 7-21 , 5.1 ng/ml) were added. Incubation was continued for another 12 h at 4 ЊC. Separation of antibody-bound from free 125 I-E 7-21 was achieved by the addition of 100 ml 1% rabbit gamma globulin and 500 ml 25% PEG 6000 at 4 ЊC. After centrifugation at 1800 g for 35 min the supernatants were removed by aspiration, another 1000 ml of PEG 6000 was added and the tubes again centrifuged as described above. The supernatants were removed and the pellets counted in a gamma counter (1277 Gammamaster, Wallac, Turku, Finland). The IGF-II RIA was carried out as described previously (33) .
Assay validation
Inter-assay variability of our pro-IGF-II E-domain assay was 26%, intra-assay variability 23%. Mean of slope factor of the dose-response curve was 0.7 Ϯ 0.07, mid-range of the assay was 2.53 Ϯ 0.93, and mean of the least-detectable concentration was 0.06 Ϯ 0.03. IGF-II concentrations are given in nmol/l related to the IGF-II standards' concentrations (nmol/l). Pro-IGF-II levels are also given in nmol/l related to the E 7-21 standard levels (nmol/l). Recovery of 2.30 nmol/l E 7-21 added to two normal sera was determined. E 7-21 concentration in serum 1 was 0.23 nmol/l, so the expected value after adding 2.30 nmol/l E 7-21 was 2.53 nmol/l, and the found value was 2.33 nmol/l. E 7-21 concentration in serum 2 was 1.51 nmol/l, so the expected value after adding 2.30 nmol/l E 7-21 was 3.81 nmol/l, and the found value was 3.44 nmol/l. For data on parallelism of standards and unknowns see Fig. 1 .
Gel electrophoresis and Western immunoblot
Aliquots of peak fractions detected by IGF-II or pro-IGF-II E-domain RIA were lyophilized, redissolved in Laemmli buffer (34) and then after denaturation electrophoresed in duplicate on a 15% SDS polyacrylamide mini gel. Electroblotting was performed on Immun-Lite membrane in 25 mmol/l Tris, 192 mmol/l glycine, 10% methanol (pH 8.2) for 60 min at 0.26-0.32 A. After washing and blocking (1 h) according to the chemiluminescent assay instructions, the membrane was cut in half (parts A and B). Parts A and B were incubated overnight with the above described pro-IGF-II E-domain antiserum at a final dilution of 1:400 in antibody buffer provided by the assay kit, or with IGF-II polyclonal antibody (1:500), respectively. Incubation with the alkaline phosphatase coupled second antibody (1:3000), final washing steps and chemiluminescent substrate incubation (35) were again carried out according to the protocol provided by Bio-Rad. All the incubation steps were performed at room temperature using an orbital shaker platform for gentle agitation. Blots were developed after 2-5 min exposure to Kodak X-ray film.
Results
Cell lines from four different Wilms' tumors and one normal kidney were established. Two of the tumors have been histologically diagnosed as classical Wilms' tumors (favourable histology), the cell lines (WTCL-1 and WTCL-2) were established after passage through nude mice (19) . The Wilms' tumor cell line 3 (WTCL-3) originated from a Wilms' tumor with a point mutation at the Wilms' tumor suppressor gene WT1 due to a Denys-Drash syndrome (arginine to tryptophan interchange at position 1558 in exon 9). It was cultured directly from the tumor after surgery. The kidney cell line (KCL-1) originated from the same patient and was cultured directly from 'healthy' kidney tissue. WTCL-4 was a cell line from a Wilms' tumor with 50% blastemal cells, partly rhabdomyosarcomatous differentiation and 10% anaplastic features and was cultured directly.
Gel permeation chromatography, IGF-II/pro-IGF-II E-domain assay and molecular weight determination of pro-IGF-II and IGF-II from peak fractions by gel electrophoresis and Western immunoblotting
Because we were mainly interested in qualitative rather than quantitative analysis of IGF-II proforms released by the Wilms' tumor cells, we did not measure each fraction from the chromatography, nor did we determine the area under the curve, but rather we tried to create IGF-II and pro-IGF-II profiles to qualitatively show the distribution of high molecular weight proforms of IGF-II released by cells generated from histologically different Wilms' tumors.
Bio-Gel P-100 chromatography of the serum-free media obtained from the cell lines WTCL-1 and WTCL-2 showed similar IGF-II RIA patterns (Fig. 2a shows that for WTCL-1). In the IGF-II RIA, peaks of IGF-II appeared at fractions number 76 (peak 1), 80-86 (peak 2) and 90-92 (peak 3) corresponding to molecular masses of approximately 12, 9 and 7 kDa according to the standards' elution profiles. In the pro-IGF-II E-domain RIA, one broad peak between fractions 72-84 was obtained (Fig. 2a) . By immunoblotting using IGF-II antiserum, proteins with molecular masses of about 7.5 kDa (fractions 90/91, peak 3), 8-18 kDa (fractions 84-86, peak 2) and 10-20 kDa (fractions 75-77, peak 1) could be detected in the two tumor media obtained from the classical Wilms' tumors (WTCL-1 and WTCL-2) (Fig. 2b) . The same fractions run over the second half of the gel (part A) were stained with the pro-IGF-II E-domain antiserum. Fraction 90/91 (peak 3) gave no band as expected; fractions 84-86 (peak 2) gave a major band at 8-10 kDa, a minor band at about 15 kDa (WTCL-1; Fig. 2b ) and bands at 16-18 kDa (WTCL-2); fractions 75-77 (peak 1) gave bands at 10-21 kDa (Fig. 2b) .
Chromatography and immunoblotting studies of conditioned medium from the WTCL-3 cell lines carried out in the same manner as described above gave different profiles. Over the entire chromatography profile, IGF-II concentrations in the measured fractions were lower than in the ones from WTCL-1 or -2, but higher than in the medium from normal kidney cells of the same patient generated under the same conditions (KCL-1) (20) . Using the pro-IGF-II E-domain assay a higher peak of pro-IGF-II compared with IGF-II could be seen in WTCL-3 media. By immunoblotting using IGF-II antiserum bands at 10-20 kDa were observed. No 7.5 kDa IGF-II could be detected using IGF-II antiserum. When stained with the pro-IGF-II E-domain antiserum bands at 15-25 kDa could be observed.
The same studies carried out with WTCL-4 media also revealed a lower amount of IGF-II in the measured fractions compared with WTCL-1 and -2 using the IGF-II assay. The IGF-II concentrations were more comparable to the IGF-II concentrations measured in the WTCL-3 media but showed a small but distinct peak at a higher molecular weight range. Pro-IGF-II E-domain measurement of certain WTCL-4 fractions showed almost no pro-IGF-II. With the cell line WTCL-4, which secreted the lowest amount of IGF-II and pro-IGF-II into the culture medium, only a pool from the higher molecular weight peak seen by IGF-II measurement could be successfully used for molecular weight determination; bands between 18 and 20 kDa appeared using pro-IGF-II E-domain antiserum.
The discrepancies of the two antibodies in recognizing IGF-II proforms either in solution or in the Western blot might be due to steric reasons resulting in different tertiary structures of the IGF-II proforms or due to the fact that for Western blotting the probes have been highly concentrated.
Discussion
Up to now the intermediate stages of processing of pro-IGF-II are not known. In analogy to the processing of pro-IGF-II by Buffalo rat hepatocytes (36), pro-IGF-II may be processed by multiple step cleavage of an 89 amino acid-containing E-domain via an initial precursor of about 20 kDa to a final 8.7 kDa proform (21) . Pro-IGF-II forms of various molecular masses from 10 to 16 kDa and different naturally occurring IGF-II variants have been found in normal and tumor tissues (24, 25, 27, 28, 30, (37) (38) (39) (40) . For some of them it was shown that the presence of the terminal extension, i.e. the E-domain, does not affect binding affinity either to type-1 (24) or type-2 IGF receptor or to rat IGF binding protein (IGFBP)-2 (27) or human IGFBP-3 or IGFBP-2 (41) whereas it was more (27) . For other forms of pro-IGF-II the affinity towards the type-1 or type-2 IGF receptor and towards IGF binding proteins has been shown to be decreased (30, 38, 40) . Interestingly, Hoeflich et al. (42) recently showed that human embryonal kidney fibroblasts transfected with the fulllength human IGF-II cDNA partially overexpressed a 17 kDa pro-IGF-II which in excessive concentrations was able to modulate the targeting of a portion of lysosomal enzymes by enhancing the secretion of newly synthesized enzymes and/or by affecting their re-uptake mechanism. It was also demonstrated recently that pro-IGF-II secreted by a non-islet cell tumor inhibited the binding of ALS (acid-labile subunit) to IGFBP-3 in vitro being the primary cause of hypoglycemia in those tumor patients (43) . Furthermore Hudgins et al. (37) speculated that IGF-II precursors may be less susceptible to proteolytic degradation due to glycosylation and sialidation.
The existence of various IGF-II proforms with molecular masses ranging from 25 to 8 kDa produced and released by Wilms' tumor cells in vitro -as shown in our experiments -may fit the hypothesis about the processing of 7.5 kDa IGF-II. Our IGF-II and pro-IGF-II E-domain antibodies each recognize high molecular weight forms of IGF-II of more than one kind, as can be seen by comparing the IGF-II and pro-IGF-II assay data of the chromatographed tumor media and the different molecular weight forms found in identical fractions after immunoblotting with either IGF-II E-domain or IGF-II antibodies. Whether those different proforms represent IGF-II with a different degree of E-domain truncation or the same one with a different degree of glycosylation cannot be distinguished by this study. It was not possible to determine the exact pro-IGF-II/IGF-II ratio in the different cell lines because the IGF-II antibodies also bound to some of the pro-IGF-II forms. Interestingly, the IGF-II and pro-IGF-II E-domain profiles of the chromatographed culture medium obtained from cell cultures WTCL-1 and WTCL-2 are very similar, but differ from those of the WTCL-3 and WTCL-4 cell lines.
In conclusion, cultured Wilms' tumor cells derived from histologically different Wilms' tumors produce and release different amounts of IGF-II proforms with molecular masses ranging from 25 to 10 kDa. Whether or not criteria like the quantity or quality of IGF-II proforms produced by the tumor cells are relevant for cell growth and differentiation and therefore for histological classification and prognosis of the Wilms' tumors remains to be examined. Interestingly, various IGF-II proforms seem to appear also in serum of patients with Wilms' tumors and of patients with non-islet cell tumor hypoglycemia (Schmitt S, in preparation). However, the synthesis and release of different high molecular weight IGF-II proforms by histologically different Wilms' tumors might give evidence that not only the fully processed 7.5 kDa IGF-II but also its various proforms might contribute to the critical role of IGF-II as an important auto-and paracrine stimulator for growth of cells of embryonic origin (20) .
